Alagille Syndrome: Features and Outcome among Filipino Children

Germana Emerita V. Gregorio and Jossie M. Rogacion

Department of Pediatrics, College of Medicine and Philippine General Hospital, University of the Philippines Manila

ABSTRACT

We report 13 children fulfilling criteria of Alagille syndrome. All had chronic cholestasis secondary to paucity of intrahepatic bile ducts and triangular facies. Eight children had associated congenital heart disease (six pulmonic stenosis, one each tetralogy of Fallot and patent ductus arteriosus), seven with butterfly vertebrae and one with posterior embryotoxon. Seven of the 13 children are alive and jaundice-free but three with concomitant hypercholesterolemia; the six other children died of liver-related complications.

Key Words: Butterfly vertebrae, infantile jaundice, facial malformation, paucity of intrahepatic bile ducts

INTRODUCTION

Alagille syndrome (AGS) is an autosomal dominant disorder characterized by the presence of at least three of five major criteria: 1) chronic cholestasis secondary to paucity of intrahepatic bile ducts (IHBD); 2) congenital heart disease; 3) facial dysmorphism; 4) butterfly vertebrae and 5) posterior embryotoxon.\(^1\,^4\) Two additional phenotypic criteria have been proposed — abnormalities of the kidneys and abnormalities of the vasculature — which are also important manifestations of AGS. Moreover, the presence of two major criteria with confirmed AGS in a first-degree relative may also be sufficient for a diagnosis.\(^5\)

The disease is caused by a mutation in the Jagged-1 gene, which is important in cell differentiation and regulation during the development of the biliary epithelium.\(^6\,^9\) Once a diagnosis of AGS is made, the treatment and outcome are largely determined by the extent of the hepatic and cardiac disorders.\(^9\,^{10}\) The most common cardiovascular anomaly is the presence of peripheral pulmonic stenosis in 35 to 85% of AGS; in around 30% of cases, it maybe either atrial or ventricular septal defect, tetralogy of Fallot or pulmonary atresia.\(^1\,^4\,^{11},^{12}\) Progressive liver failure due to paucity of IHBD\(^13\) or growth impairment, refractory pruritus and debilitating xanthomas due to chronic cholestasis may occur.\(^9\,^{10}\) Development of hepatocellular carcinoma has also been reported in children with AGS,\(^14\) the youngest of whom was a 3-year-old.\(^15\)

AGS occurs in 1 in 100,000 live births but the incidence may be underestimated.\(^16\) It has never been reported among Filipino children. This study describes 13 patients diagnosed with AGS at the Section of Pediatric Gastroenterology, Hepatology and Nutrition of the Philippine General Hospital from 2000–2018. The clinical, biochemical, histological features and outcomes of these patients are discussed.
MATERIALS AND METHODS

Based on the accepted criteria in the year 2000 at the time this study was initiated, AGS was diagnosed if at least three of the five major clinical features were present.\(^1^\)\(^4\) Chronic cholestasis was defined as persistence of direct hyperbilirubinemia beyond 6 months of age.\(^3\) All patients underwent percutaneous liver biopsy and paucity of IHBD was reported as present if the ratio of the number of intralobular bile ducts to the number of portal tracts was less than 0.5.\(^1^6\)\(^1^7\) The presence of congenital heart disease based on physical examination was confirmed by 2D echocardiogram. The presence of any vertebral anomalies was noted on radiologic evaluation of the vertebrae. Ophthalmologic examination, consisting of gonioscopy and slit lamp examination, was performed to assess presence of posterior embryotoxon. The cholesterol and triglyceride levels were considered increased if the values were beyond the upper limit for the age of the patient. Standard liver function tests, prothrombin time and international normalized ratio (INR) were done at baseline and on follow up as needed.

Parents were informed and agreed that the data of the patients will be included in this case series of patients with Alagille syndrome.

RESULTS

Clinical features

During the study period, 13 children (8 males) were diagnosed to have AGS (Table 1). All patients had a history of jaundice starting on the first month of life; the mean age of consult with a physician for the jaundice was 3 months (range, 2–9). Of the 13, 5 underwent initial liver biopsy at mean age of 2.5 months (range, 2 to 3.5) and was interpreted as giant cell hepatitis. However, one of the five patients had persistent acholic stools and eventually underwent a hepaticojejunostomy operation after an intraoperative cholangiogram that showed no passage of dye in the duodenum. In these five patients, paucity of IHBD (Figure 1) was only documented during the second liver biopsy that was done at a mean age of 23 months (range, 11 to 50) after the first one. For the remaining eight patients, paucity of IHBD was documented during the initial liver biopsy performed later at mean age of 18 months (range, 3 to 38). Other characteristic features that were noted in this case series included characteristic triangular facies in all patients, presence of congenital heart disease in eight, vertebral anomalies in nine and posterior embryotoxon in one patient. The vertebral anomalies consisted of butterfly vertebrae in seven, and spina bifida and scoliosis in one each. One patient also had clubfoot. Other anomalies identified

---

**Table 1. Clinical features of 13 patients diagnosed with Alagille's Syndrome**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex</th>
<th>Age at Initial Consult (months)</th>
<th>Age at Diagnosis (months)</th>
<th>Facial Feature</th>
<th>Congenital heart disease</th>
<th>Skeletal Abnormality</th>
<th>Posterior Embryotoxon</th>
<th>Other anomalies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>2.0</td>
<td>19.3</td>
<td>Present</td>
<td>None</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td>Regal agenesis</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>2.2</td>
<td>17.8</td>
<td>Present</td>
<td>Pulmonic Stenosis</td>
<td>Clubfoot</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>1.6</td>
<td>28.2</td>
<td>Present</td>
<td>Patent Ductus Arteriosus</td>
<td>None</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>3.1</td>
<td>50.3</td>
<td>Present</td>
<td>Bilateral Pulmonic Stenosis</td>
<td>Spina Bifida</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>3.5</td>
<td>11.9</td>
<td>Present</td>
<td>Pulmonic Stenosis</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>10.3</td>
<td>10.5</td>
<td>Present</td>
<td>Pulmonic Stenosis, valvar with pulmonary valve annulus of 0.8cm</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>3.0</td>
<td>8.1</td>
<td>Present</td>
<td>None</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>3.1</td>
<td>30.1</td>
<td>Present</td>
<td>Tetralogy of Fallot with moderate valvar to supravalvular pulmonic stenosis</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>3.1</td>
<td>38.4</td>
<td>Present</td>
<td>None</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td>Gall bladder polyps</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>3.4</td>
<td>24.6</td>
<td>Present</td>
<td>None</td>
<td>Scoliosis</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>2.1</td>
<td>7.1</td>
<td>Present</td>
<td>Pulmonic Stenosis, supravalvular</td>
<td>None</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>2.8</td>
<td>2.8</td>
<td>Present</td>
<td>Pulmonic Artery Stenosis, left and right</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>28.6</td>
<td>28.6</td>
<td>Present</td>
<td>None</td>
<td>Butterfly vertebrae</td>
<td>Absent</td>
<td></td>
</tr>
</tbody>
</table>

---

Figure 1. Liver biopsy of a patient (patient #9) with Alagille Syndrome showing a portal tract with absence of bile duct and only the hepatic artery and veins are present.
were renal agenesis and gall bladder polyps; the latter was eventually excised when the patient developed acute cholecystitis at 5 years of age.

Biochemical features

Baseline biochemical examinations showed that all patients had markedly elevated bilirubin and enzyme levels (Table 2). All had normal international normalized ratio. The serum albumin values were less than 30 g/L in three cases. On follow-up in 11 patients, there were elevated cholesterol levels in 9 patients (Mean 6.8 mmol/L [SD 3.6]; NV < 5.2), and elevated triglyceride levels in 10 patients (Mean 2.7 mmol/L [SD 1.2]; NV < 1.0).

Outcome

Of the 13 patients, seven are alive and six died. Those who are alive were followed up for a mean duration of 5.8 years (range, 2–15) after diagnosis. In all seven living patients, the jaundice disappeared and their development was at par with age. Weight was appropriate for height although there was linear growth retardation (Weight for height Z score < -3). Three of the seven had hypercholesterolemia, with values of 5.5, 7.2 and 9.37 mmol/L; the latter two opted for treatment with cholestyramine. All three developed debilitating xanthomas (Figure 2).

The six patients who died were followed up for mean duration of 6.4 years (range, 3 to 11) from the time of diagnosis. All had persistent jaundice, poor weight gain and linear growth, severe pruritus, xanthomas and signs of decompensated liver disease, including presence of ascites and deranged prothrombin time unresponsive to vitamin K administration. All were advised liver transplantation for long-term survival. The cause of death was liver failure before transplant could be done in 3 patients including a boy who was initially diagnosed with extrahepatic biliary atresia and underwent a hepaticojejunostomy operation. One 5-year-old patient had sudden death with no autopsy performed. Two patients died post-liver transplant surgery;

Table 2. Laboratory features of 13 patients at the time of diagnosis of Alagille’s Syndrome, mean ± SD

<table>
<thead>
<tr>
<th>Test</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bilirubin, μmol/L (nv: ≤20)</td>
<td>265.1</td>
<td>211.0</td>
</tr>
<tr>
<td>Direct bilirubin, μmol/L (nv: ≤20)</td>
<td>188.3</td>
<td>111.2</td>
</tr>
<tr>
<td>Alanine transaminase, IU/L (nv: ≤50)</td>
<td>246.8</td>
<td>164.7</td>
</tr>
<tr>
<td>Aspartate aminotransferase, IU/L (nv: ≤50)</td>
<td>293.1</td>
<td>147.7</td>
</tr>
<tr>
<td>Gamma glutamyl transpeptidase, IU/L (nv: ≤50), (n=9)</td>
<td>758.4</td>
<td>778.1</td>
</tr>
<tr>
<td>Alkaline phosphatase, IU/L (nv: ≤350)</td>
<td>673.1</td>
<td>442.0</td>
</tr>
<tr>
<td>Albumin, g/L (nv: 35-50)</td>
<td>31.8</td>
<td>6.2</td>
</tr>
<tr>
<td>International normalized prothrombin ratio (nv: 1.0-1.2)</td>
<td>1.1</td>
<td>0.04</td>
</tr>
<tr>
<td>Cholesterol, mmol/L (nv: &lt;4.2) (n=11)</td>
<td>6.8</td>
<td>3.6</td>
</tr>
<tr>
<td>Triglycerides, mmol/L (nv: &lt;1.0) (n=11)</td>
<td>2.7</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Figure 2. Debilitating xanthomas of patients with Alagille Syndrome and hypercholesterolemia in the (A) arms, (B) hands, (C) abdomen and (D) legs.
one from unexpected intracranial bleeding at six weeks and the other from acute respiratory distress syndrome within a week after the surgery.

**DISCUSSION**

Over an 18-year period, we have diagnosed 13 Filipino children with Alagille syndrome based on clinical and liver histological features. Worldwide, the incidence of the disease is 1: 40,000 to 1: 100,000 and comprised 7% of all neonatal cholestasis cases in a specialized liver center in the United Kingdom. In a local 5-year survey from 2006–10, 9 of 376 (2.4%) cases presenting with jaundice in infancy were diagnosed as Alagille syndrome. Among Asians, Alagille syndrome has only been reported as case reports from India, China and in genetic studies among Vietnamese cohorts. It has never been reported among Filipino children.

All our patients paucity of IHBD was documented histologically defined as a ratio of bile ducts to portal tracts of less than 0.5 in a specimen with at least six portal tracts. In five patients, a repeat liver biopsy was needed to make a diagnosis of paucity of IHBD since the initial one only showed non-specific giant cell hepatitis. This data is in conformity with studies showing that 25% of liver biopsies taken even after one year of age may still not show paucity of IHBD. Currently, liver biopsy is no longer considered mandatory to make a diagnosis. In the absence of the characteristic histological feature, a patient may still be classified as Alagille syndrome in the presence of cholestasis and two other classic criteria: either facial dysmorphism, congenital heart disease, skeletal and ophthalmologic abnormalities, and renal and vascular defects.

The characteristic facial features of Alagille syndrome consist of a broad forehead and deep-set eyes with pointed chin giving the face a triangular shape. Although 70 to 98% of patients diagnosed with Alagille syndrome have the characteristic facial feature, this may not be present at onset and may develop only over time. In all our patients, the diagnosis based on the presence of the facial feature was not suspected before referral to our institution. Another clue to the diagnosis of Alagille syndrome is the presence of a cardiac murmur on auscultation in a jaundiced infant. Eight patients in this series had concomitant congenital heart disease, the majority of which were peripheral pulmonic stenosis. In larger cohorts of patients with Alagille syndrome, the prevalence of cardiac murmur is higher at 85 to 98%. Other features of this syndrome include vertebral anomalies that are documented in 33 to 85% and posterior embryotoxon in 56 to 88% of cases. In our series, nine of our 13 patients had vertebral anomaly, in keeping with the reported prevalence worldwide, but only one had posterior embryotoxon, a prominent Schwalbe ring at the junction of the cornea and iris. Whether the absence of posterior embryotoxon in the anterior chamber was only missed out on routine ophthalmologic examination or this is a phenotypic variation of Alagille syndrome in our race remains to be known. It has been suggested that abnormal accumulation of protein and calcium salts in the optic nerve (optic nerve drusen) was more common than the presence of posterior embryotoxon (91% vs 69%) among 32 patients with AGS.

Since infants with Alagille syndrome will present as neonatal cholestasis, i.e., persistent jaundice beyond two weeks of life, a hepatobiliary ultrasound is important to exclude other liver pathologies such as biliary atresia. Ultrasound findings favoring the diagnosis of Alagille syndrome over biliary atresia include the absence of triangular cord sign, hepatic artery enlargement and signs of portal hypertension, such as splenomegaly and ascites. A small gallbladder appeared in both Alagille syndrome (86%) and biliary atresia (81%) on ultrasound. Similarly, non-visualization of the extrahepatic biliary tree on magnetic resonance cholangiopancreatography did not differ significantly between the two conditions (75%, Alagille vs 93%, biliary atresia). Another imaging study, such as hepatobiliary iminodiacetic acid scan, is also not specific for Alagille syndrome since the absence of passage of dye from the bile ducts to the duodenum may lead to a diagnosis of biliary atresia.

The outcome for liver disease among patients diagnosed with Alagille syndrome may be extremely variable. In a longitudinal study of laboratory parameters among patients with Alagille syndrome, a direct bilirubin greater than 77 µmol/L and cholesterol greater than 13.5 µmol/L below 5 years of age was shown to be associated with a more severe liver disease in later life. The presence of cholestasis in infancy in the seven patients who are alive, which was controlled with medical treatment, is consistent with this observation. In contrast, the six patients who have died had unremitting cholestasis that included persistent jaundice, severe pruritus, xanthelasma and evidence of synthetic dysfunction of liver.

Liver transplantation in Alagille syndrome is a therapeutic option with a reported 1-year survival between 80 to 85%. However, one must carefully screen for suitable transplant candidates. The operation may resolve cholestasis and improve quality of life but the concomitant renal disease may worsen with intake of nephrotoxic immuno-suppressant drugs. Majority of studies showed that linear growth does not improve even after successful operation. Two of our patients who underwent liver transplant died: one, from unexplained intracranial bleeding and the other from acute respiratory distress syndrome. In a study of Alagille syndrome, 25 of 268 (9%) patients were noted to have vascular complications but only 16 had documented vessel abnormalities. In the nine remaining patients (8 children) without structural lesions, two were children who developed intracranial bleeding post-liver transplant. Other cerebral abnormalities present in Alagille syndrome include Moyamoya arteriopathy, cerebral aneurysm and dolichoectasia. On the other hand, 16% (17/104) of patients who underwent liver transplant for end-stage liver disease developed acute respiratory distress syndrome between one to four days after transplant.
In summary, Alagille syndrome should be included in the differential diagnosis of any child with chronic cholestasis, especially in the presence of the characteristic facies and a cardiac murmur on auscultation. Liver transplantation is a therapeutic option for patients with unremitting cholestasis and intractable pruritus but needs careful evaluation due to the multisystem nature of this condition.

Statement of Authorship
Both authors participated in data collection and analysis, and approved the final version submitted.

Author Disclosure
Both authors declared no conflicts of interest.

Funding Source
None.

REFERENCES